Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank, has been granted renewed Foundation for the Accreditation of Cellular Therapy (“FACT ...
The revenues for the first quarter of fiscal 2026 were $7.68 million compared to $7.97 million for the first quarter of fiscal 2025. The revenues for the first quarter of fiscal 2026 consisted of ...
OLDSMAR, Fla.--(BUSINESS WIRE)-- Cryo-Cell International, Inc. (CCEL) (NYSE American LLC: CCEL) (the “Company”, “Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells ...
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced ...
The Company reported a net loss of $2.4 million in fiscal 2025 or $0.30 per basic and diluted share, compared to net income of $402,000 in fiscal 2024 or $0.05 per basic and diluted share. Due to ...
The Company reported net income of $356,000, or $0.04 per basic and diluted common shares for the three months ended May 31, 2025, compared to net income of $656,000, or $0.08 per basic and diluted ...
OLDSMAR, Fla.--(BUSINESS WIRE)-- Cryo-Cell International, Inc. (CCEL) (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, ...
The Company reported net income of approximately $47,000 or $0.01 per basic and diluted common share for the three months ended February 28, 2026, compared to net income of approximately $283,000, or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results